DA-1726 Phase 1 IND Filing Expected by Year End 2023
Board Strengthened with Recent Appointment of Industry Veteran, James P. Tursi, M.D.
Cash and Cash Equivalents of $25.8 Million, Expected to Fund.
/PRNewswire/ NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company on a quest to transform cardiometabolic diseases, today.